Glenmark Pharma Shares Rise After IGI Unveils New Solid Tumour Drug Candidate ISB 2301

Glenmark Pharmaceuticals Limited shares traded higher on Thursday after Ichnos Glenmark Innovation (IGI) announced a new development candidate, ISB 2301, aimed at treating multiple solid tumour indications.

The biotechnology company stated that ISB 2301 is a first-in-class multispecific immune cell activator designed to target three tumour-associated antigens while engaging both T cells and natural killer (NK) cells to trigger tumour cell death.

Glenmark Pharma Share Price Movement

As of 11:48 AM IST on May 21, 2026, Glenmark Pharmaceuticals shares were trading at ₹2,395.80, up ₹16.80 or 0.71% from the previous close of ₹2,379 on the NSE.

The stock remained in focus following the announcement related to IGI’s oncology pipeline.

Details of ISB 2301

IGI stated that ISB 2301 has been developed as a next-generation multispecific antibody for potential use in solid tumour treatment.

According to the company, the candidate simultaneously targets three tumour-associated antigens and activates both T cells and NK cells to stimulate an immune response against cancer cells.

The therapy has been engineered to induce antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition and a sustained type-1 immune response.

Developed Using BEAT® Technology Platform

The company said its proprietary BEAT® platform enabled the development of ISB 2301.

IGI noted that the platform supports the engineering of complex multispecific antibodies while allowing manufacturing through a standard multispecific antibody production process.

The company also stated that ISB 2301 demonstrated favourable pharmacokinetics, tolerability and safety profiles in non-human primate studies.

Clinical Development Timeline

IGI intends to submit an Investigational New Drug (IND) application for ISB 2301 by the end of 2026.

The company said it plans to begin clinical studies in 2027 as part of the next phase of development for the therapy candidate.

Management Commentary on Oncology Pipeline

Lida Pacaud, President and Chief Executive Officer of IGI, stated that ISB 2301 was designed to address the biological complexity of solid tumours through a multi-mechanistic approach involving multiple tumour targets and immune cell activation.

The company also referred to the earlier clinical progress of its investigational asset ISB 2001, which had resulted in a collaboration with AbbVie.

Read More: LPG Prices in India Today, May 21, 2026: Check Latest Rates Across Delhi, Mumbai, and Other Cities.

Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi.

Conclusion

IGI’s announcement of ISB 2301 marks another development in its multispecific antibody oncology programme focused on solid tumours. Investors are likely to monitor the planned IND filing and future clinical trial progress as the therapy advances toward human studies.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.